Sign in

You're signed outSign in or to get full access.

Alan Stewart

Director at Calidi Biotherapeutics
Board

About Alan R. Stewart

Independent Class I director at Calidi Biotherapeutics (since October 10, 2023) with deep finance and M&A experience; currently CFO of SoundThinking, Inc., a publicly traded SaaS company. Credentials include an MBA in Finance from Harvard Business School, a B.S. with Distinction in Oceanography from the U.S. Naval Academy, and prior FINRA Series 63/79 (inactive). The board has affirmatively determined Stewart is independent under NYSE American standards .

Past Roles

OrganizationRoleTenureCommittees/Impact
Fit Advisors, LLCPresidentNot disclosedLaunched consultancy; completed numerous M&A transactions
RA Capital Advisors, LLCManaging DirectorNot disclosedSpecialized in M&A and financing transactions

External Roles

OrganizationRolePublic/PrivateTenure/Notes
SoundThinking, Inc.Chief Financial OfficerPublicLed Nasdaq IPO; growth and acquisitions of tech providers

Board Governance

  • Classification and tenure: Class I director; board is staggered into Classes I–III . Stewart serves in Class I alongside CEO Eric Poma .
  • Independence: Determined independent; also independent for audit and nominating committee service .
  • Committee assignments:
    • Audit Committee: Chair (member: Stewart, Schoeneck; Schoeneck is the committee’s financial expert) .
    • Nominating & Corporate Governance Committee: Member (chair: Leftwich; members: Leftwich, Schoeneck, Stewart) .
    • Compensation Committee: Not a member (members: Schoeneck [chair], Leftwich, Peoples) .
  • Attendance: Board met 24 times (Audit: 5; Compensation: 4; Nominating: 2). Each director during FY2024 attended at least 75% of meetings of the Board and committees on which they served; quorum at each meeting .
  • Board leadership: Independent chair (Schoeneck); CEO and chair roles separated as of April 22, 2025 .

Fixed Compensation (Non‑Employee Director, FY2024)

ComponentAmount (USD)Notes
Fees earned or paid in cash$14,688Board/committee cash retainer/meeting fees
Total fixed compensation$14,688

Performance Compensation (Non‑Employee Director, FY2024)

Award TypeGrant‑date Fair Value (USD)Outstanding as of 12/31/2024 (shares)Vesting/Terms
Restricted Stock Units (RSUs)$44,06112,771RSUs issued under 2023 Plan; vesting terms not detailed for directors
Stock Options$15,60325,467Options generally vest over 4 years; max term 10 years
Total equity award value (FY2024)$59,664Equity awards comprise the majority of FY2024 director compensation

No performance metrics (TSR/revenue/EBITDA/ESG) are disclosed for director equity; awards appear time‑based under plan provisions .

Other Directorships & Interlocks

CompanyRolePotential Interlock/Conflict
SoundThinking, Inc.CFONone disclosed between CLDI and SoundThinking; related‑party transactions section does not identify Stewart

Expertise & Qualifications

  • Finance and capital markets (CFO; M&A transactions; IPO execution) .
  • Education: MBA, Harvard Business School; B.S. Oceanography, U.S. Naval Academy .
  • Regulatory: FINRA Series 63 and 79 (inactive) .
  • Board skills: Audit oversight (audit committee chair); governance (nominating committee member) .

Equity Ownership

MeasureShares/Units% of OutstandingAs‑ofNotes
Total beneficial ownership46,429<1%Record Date May 19, 2025Includes direct and options exercisable within 60 days
Direct common shares28,976May 19, 2025
Options exercisable ≤60 days17,453May 19, 2025
RSUs outstanding12,771Dec 31, 2024Not counted in beneficial ownership; outstanding under 2023 Plan
Shares pledged as collateralNone disclosedMay 19, 2025Company states to its knowledge no pledging by directors/nominees

Insider trades and Section 16 compliance

EventDateDetailsFiling Date
RSU grant under 2023 PlanMarch 29, 2024RSU grants to certain directors including Alan StewartForm 4 filed three months late on July 2, 2024 (administrative oversight)

Governance Assessment

  • Positives

    • Independence and committee leadership: Independent director; chairs Audit Committee and serves on Nominating & Governance—enhances oversight of financial reporting, risk, and board composition .
    • Engagement: FY2024 attendance ≥75% on board/committees; frequent board meetings signal active oversight (24 board meetings) .
    • Alignment: Holds equity (direct shares, exercisable options, RSUs outstanding); board encourages director equity ownership to align interests .
    • Compensation structure: Majority of director pay in equity (RSUs/options) vs cash, aligning with shareholder value creation .
  • Watch items / RED FLAGS

    • Late Section 16 filings: Company reports Form 4s (including Stewart’s March 29, 2024 RSUs) were filed three months late due to administrative oversight—process weakness in insider compliance .
    • Historical option repricing: Board approved a broad option repricing on January 18, 2023 (pre‑Stewart’s tenure); while not attributable to Stewart, this is a governance red flag for shareholder‑friendly pay practices and merits monitoring going forward .
    • External time commitments: Stewart serves as CFO of a public company; while common for experienced directors, investors may monitor for potential bandwidth conflicts if CLDI enters periods of elevated audit/financing complexity .
  • Conflicts/Related party exposure

    • No related‑party transactions involving Stewart are disclosed; several related‑party items involve other directors/officers (e.g., AJC Capital/Leftwich/Ng), underscoring the importance of independent audit oversight .

Policies: Code of Conduct and compensation recovery (clawback) policy adopted; clawback applies to executive compensation upon restatement per Exchange Act Section 10D/NYSE American rules .